Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors |
| |
Authors: | Nicole C. Clark Anne M. Friel Cindy A. Pru Ling Zhang Toshi Shioda Bo R. Rueda |
| |
Affiliation: | 1. Department of Animal Sciences, School of Molecular Biosciences, Center for Reproductive Biology, Washington State University, Pullman, WA, USA;2. Vincent Center for Reproductive Biology and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;3. Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA, USA |
| |
Abstract: | Triple negative breast cancers (TNBCs) are highly aggressive and grow in response to sex steroid hormones despite lacking expression of the classical estrogen (E2) and progesterone (P4) receptors. Since P4 receptor membrane component 1 (PGRMC1) is expressed in breast cancer tumors and is known to mediate P4-induced cell survival, this study was designed to determine the expression of PGRMC1 in TNBC tumors and the involvement of PGRMC1 in regulating proliferation and survival of TNBC cells in vitro and the growth of TNBC tumors in vivo. For the latter studies, the MDA-MB-231 (MDA) cell line derived from TNBC was used. These cells express PGRMC1 but lack expression of the classical P4 receptor. A lentiviral-based shRNA approach was used to generate a stably transfected PGRMC1-deplete MDA line for comparison to the PGRMC1-intact MDA line. The present studies demonstrate that PGRMC1: 1) is expressed in TNBC cells; 2) mediates the ability of P4 to suppress TNBC cell mitosis in vitro; 3) is required for P4 to reduce the apoptotic effects of doxorubicin in vitro; and 4) facilitates TNBC tumor formation and growth in vivo. Taken together, these findings indicate that PGRMC1 plays an important role in regulating the growth and survival of TNBC cells in vitro and ultimately in the formation and development of these tumors in vivo. Thus, PGRMC1 may be a therapeutic target for TNBCs. |
| |
Keywords: | Breast cancer endocrine PGRMC1 progesterone TNBC xenograft |
|
|